Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Organon & Co. (OGN)

Organon & Co. (OGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Organon to Present New Research on Access and Value at ISPOR 2026 Business Wire - Fri May 15, 6:30AM CDT

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio

OGN : 13.40 (-0.04%)
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PR Newswire - Thu May 14, 4:25PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

XOMA : 41.95 (+0.60%)
OGN : 13.40 (-0.04%)
VRE : 18.99 (-0.05%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX PR Newswire - Wed May 6, 1:27PM CDT

NEW YORK , May 6, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

XOMA : 41.95 (+0.60%)
RMAX : 8.93 (+2.29%)
HLX : 9.73 (+1.99%)
OGN : 13.40 (-0.04%)
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? PR Newswire - Mon May 4, 1:55PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

TBRG : 26.06 (+0.35%)
OGN : 13.40 (-0.04%)
CYCN : 3.08 (+2.50%)
OGN
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates StockStory - Thu Apr 30, 5:10PM CDT

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

OGN : 13.40 (-0.04%)
Organon: Q1 Earnings Snapshot AP - Thu Apr 30, 6:45AM CDT

Organon: Q1 Earnings Snapshot

OGN : 13.40 (-0.04%)
Organon Reports Results for the First Quarter Ended March 31, 2026 Business Wire - Thu Apr 30, 6:30AM CDT

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP...

OGN : 13.40 (-0.04%)
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe PR Newswire - Wed Apr 29, 9:00AM CDT

SHANGHAI , April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY...

OGN : 13.40 (-0.04%)
Organon Cancels First Quarter Earnings Call Business Wire - Wed Apr 29, 6:30AM CDT

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings...

OGN : 13.40 (-0.04%)
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe Business Wire - Wed Apr 29, 4:30AM CDT

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY ® (pertuzumab) 420 mg/14 mL...

OGN : 13.40 (-0.04%)

Barchart Exclusives

IBM Stock’s $10 Billion Quantum Catalyst Is Here Barchart - 11 minutes ago
IBM's massive quantum computing investment is strengthening its position in what could become one of the technology industry's largest long-term opportunities. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.